Approximately 4% of people aged 40 years and older have corneal endothelial disease/dystrophy (CED) affecting the back of the cornea, and corneal transplantation is the only treatment option for ...

Important insights into the mechanisms behind Fuchs endothelial corneal dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers.

In this cross section of a cornea in a person with Fuchs' dystrophy, the green rectangles represent endothelial cells. The magenta dots are outgrowths of Descemet's membrane known as guttae.

Quirónsalud Marbella Hospital has become one of the few medical centres in Spain to perform Descemet Membrane Endothelial ...

The company has completed dosing in the Phase 1 trial for DT-168 targeting Fuchs Endothelial Corneal Dystrophy and expects to release data in the first half of 2025. Additionally, Design aims to ...

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, ...

Her laboratory is responsible for identification of genes for many different diseases, most recently for Age-Related Macular Degeneration (AMD) and Fuchs’ Endothelial Corneal Dystrophy (FECD). Her ...